Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Bristol-Myers Squibb
Study ID
NCT06551129
Status
Recruiting
Apply to this trial

Conditions

  • Obstructive Hypertrophic Cardiomyopathy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Mavacamten — DRUG
    As prescribed by treating physician

Study Details

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.

Key Dates

Start date
May 10, 2024
Status verified
Nov 2024
Primary completion
Dec 31, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
118 participants (estimated)

Arms

  • Arm: Mavacamten
    Adult participants with symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten

Primary Outcome Measure

Participant Hypertrophic Cardiomyopathy symptoms as assessed by Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ v2,0 - 7-day recall version) [ Time Frame: Baseline and weeks 2, 4, 8, 12, 24, 30, 48, 60, 72, 84 and 96 ]

Central Contacts

  • BMS Study Connect Contact Center www.BMSStudyConnect.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
Analysis Group Inc.BostonMassachusetts02199
Min Yang, Site 0001
[email protected]

Find similar trials in Boston, MA

By research site
Analysis Group Inc.· Boston, MA

Related Studies